Given that oligodendrocytes may substantially contribute to Aβ production, selectively targeting Aβ generation in these cells could offer a therapeutic approach for AD that minimizes the negative effects associated with BACE1 upregulation [25]. This evidence concerns the gene BACE1 and Alzheimer disease.